Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study

Author:

Dignass Axel1,Redondo Isabel2,Streit Petra3,Hartz Susanne4,Gurses Gamze5,Knight Hannah6,Barlow Sophie6,Harvey Niamh6ORCID,Hunter Theresa7ORCID

Affiliation:

1. Department of Medicine I, Agaplesion Markus Hospital, Goethe University, Frankfurt/Main, Germany

2. Eli Lilly and Company, Lisbon, Portugal

3. Eli Lilly and Company, Vernier, Switzerland

4. Eli Lilly and Company, Bracknell, UK

5. Eli Lilly and Company, Istanbul, Turkey

6. Adelphi Real World, Bollington, UK

7. Eli Lilly and Company, Indianapolis, Indiana, USA

Funder

Eli Lilly and Company

Publisher

Informa UK Limited

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3